anti-CLL-1 CAR-T

Anti-CLL-1 CAR-T cell therapy is a specialized form of adoptive cell immunotherapy designed to treat myeloid malignancies, particularly relapsed or refractory acute myeloid leukemia (AML). These therapies involve T cells—either autologous or allogeneic—genetically modified to express a chimeric antigen receptor (CAR) that targets C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A). CLL-1 is a compelling therapeutic target because it is highly expressed on AML blasts and leukemic stem cells (LSCs) but is absent on healthy hematopoietic stem cells, potentially allowing for the eradication of the leukemia while sparing the bone marrow's regenerative capacity. A prominent example in development is Caribou Biosciences' CB-012, an allogeneic CAR-T engineered with next-generation CRISPR technology to include genomic edits (such as TRAC, B2M-HLA-E, and PDCD1 knockouts) intended to prevent graft-versus-host disease, evade immune rejection, and resist exhaustion within the tumor microenvironment.

Other names

CLEC12A CAR-TCLEC-12A CAR-TCLEC 12A CAR-TCLL-1 CAR-TCLL1 CAR-TCLL 1 CAR-Tanti-CLEC12A CAR-Tanti-CLEC-12A CAR-Tanti-CLEC 12A CAR-T